{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T12:12:44Z","timestamp":1756901564298,"version":"3.44.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>A simple, sensitive, and specific liquid chromatography\u2013tandem mass spectrometry (LC\u2013MS\/MS) method was successfully developed and validated to determine navitoclax and doxorubicin in rat plasma. Ketoconazole and daunorubicin were employed as internal standards to ensure accurate quantification and method consistency. The sample preparation involved a straightforward protein precipitation technique, which facilitated efficient extraction of the analytes from the plasma matrix. The resulting supernatant was subjected to drying using a vacuum concentrator and later reconstituted before being injected into the LC\u2013MS system. Separation was carried out using a SHIMADZU Shim-pack GIST C-18 column with mobile phase, consisting of a carefully balanced mixture of acetonitrile and water with 0.1% formic acid, with a flow rate of 0.5\u00a0mL\/min. This composition ensured efficient elution and minimized matrix effects, contributing to the method\u2019s robustness and reproducibility. The developed method was comprehensively validated according to regulatory guidelines, assessing various parameters including specificity, selectivity, sensitivity, calibration curve performance, precision, accuracy, stability and dilution integrity. This bioanalytical method has the potential to be extended to various clinical settings, enabling the monitoring drug metabolism, monitoring potential drug\u2013drug interactions and understanding the pharmacokinetic profile and adverse effect potential of the combination therapy.<\/jats:p>","DOI":"10.1093\/chromsci\/bmaf046","type":"journal-article","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T10:06:29Z","timestamp":1756548389000},"source":"Crossref","is-referenced-by-count":0,"title":["Simultaneous Bioanalytical Method Development and Validation of Navitoclax and Doxorubicin in Rat Plasma Using UHPLC-HESI-LTQ-MS"],"prefix":"10.1093","volume":"63","author":[{"given":"Nitesh","family":"Rai","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Analysis , National Institute of Pharmaceutical Education and Research (NIPER), Sila Katamur (Halugurisuk), P.O. Changsari, District Kamrup, Assam \u2013 781101,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analysis , National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S.A.S. Nagar, Mohali \u2013 160062, Punjab,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parul","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analysis , National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S.A.S. Nagar, Mohali \u2013 160062, Punjab,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pirangi","family":"Srikanth","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analysis , National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S.A.S. Nagar, Mohali \u2013 160062, Punjab,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaik Khaja","family":"Moinuddin","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analysis , National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S.A.S. Nagar, Mohali \u2013 160062, Punjab,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pramod","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analysis , National Institute of Pharmaceutical Education and Research (NIPER), Sila Katamur (Halugurisuk), P.O. Changsari, District Kamrup, Assam \u2013 781101,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1585-5322","authenticated-orcid":false,"given":"Sukhendu","family":"Nandi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analysis , National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S.A.S. Nagar, Mohali \u2013 160062, Punjab,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,8,30]]},"reference":[{"volume-title":"Medicine and the five senses","year":"1993","author":"Bynum","key":"2025083006312293100_ref1"},{"volume-title":"The emperor of all maladies: A biography of cancer","year":"2010","author":"Mukherjee","key":"2025083006312293100_ref2"},{"issue":"4","key":"2025083006312293100_ref3","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1017\/S0007087416001175","article-title":"A pathology of progress? Locating the historiography of cancer","volume":"49","author":"Arnold-Forster","year":"2016","journal-title":"The British Journal for the History of Science"},{"issue":"2","key":"2025083006312293100_ref4","first-page":"87","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA: a Cancer Journal for Clinicians"},{"issue":"3","key":"2025083006312293100_ref5","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: a Cancer Journal for Clinicians"},{"issue":"1","key":"2025083006312293100_ref6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41591-020-01195-4","article-title":"Targeting metastatic cancer","volume":"27","author":"Ganesh","year":"2021","journal-title":"Nature Medicine"},{"issue":"2","key":"2025083006312293100_ref7","doi-asserted-by":"crossref","first-page":"e044420","DOI":"10.1136\/bmjopen-2020-044420","article-title":"Retrospective cohort study evaluating clinical, biochemical and pharmacological prognostic factors for prostate cancer progression using primary care data","volume":"11","author":"Merriel","year":"2021","journal-title":"BMJ Open"},{"issue":"3","key":"2025083006312293100_ref8","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: a Cancer Journal for Clinicians"},{"issue":"10272","key":"2025083006312293100_ref9","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0140-6736(21)00001-5","article-title":"Global variation in postoperative mortality and complications after cancer surgery: A multicentre, prospective cohort study in 82 countries","volume":"397","author":"Knight","year":"2021","journal-title":"The Lancet"},{"issue":"6","key":"2025083006312293100_ref10","first-page":"891","article-title":"Modifying the tumor microenvironment using nanoparticle therapeutics","volume":"8","author":"Roy","year":"2016","journal-title":"Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology"},{"issue":"23","key":"2025083006312293100_ref11","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"8","author":"Mokhtari","year":"2017","journal-title":"Oncotarget"},{"key":"2025083006312293100_ref12","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.3389\/fphar.2018.01300","article-title":"Evolution of cancer pharmacological treatments at the turn of the third millennium","volume":"9","author":"Falzone","year":"2018","journal-title":"Frontiers in Pharmacology"},{"issue":"6","key":"2025083006312293100_ref13","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1177\/153303460800700611","article-title":"Recent advances in protection against doxorubicin-induced toxicity","volume":"7","author":"Injac","year":"2008","journal-title":"Technology in Cancer Research & Treatment"},{"issue":"10","key":"2025083006312293100_ref14","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s002680010200","article-title":"Molecular analysis of mechanisms regulating drug sensitivity and the development of new chemotherapy strategies for genitourinary carcinomas","volume":"24","author":"Naito","year":"2000","journal-title":"World Journal of Surgery"},{"issue":"8","key":"2025083006312293100_ref15","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1039\/D0BM00112K","article-title":"Ultra pH-sensitive polymeric nanovesicles co-deliver doxorubicin and navitoclax for synergetic therapy of endometrial carcinoma","volume":"8","author":"Ding","year":"2020","journal-title":"Biomaterials Science"},{"issue":"1","key":"2025083006312293100_ref16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1773-2247(14)50004-4","article-title":"Potential of pH-sensitive polymer-anchored cationic liposomes for combinatorial anticancer therapy with doxorubicin and siRNA","volume":"24","author":"Jeong","year":"2014","journal-title":"Journal of Drug Delivery Science and Technology"},{"issue":"3","key":"2025083006312293100_ref17","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.molcel.2004.12.030","article-title":"Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function","volume":"17","author":"Chen","year":"2005","journal-title":"Molecular Cell"},{"issue":"24","key":"2025083006312293100_ref18","first-page":"5807","article-title":"Bcl-2, Bc,l-xL, and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells","volume":"119","author":"M\u00e9rino","year":"2012","journal-title":"Blood, The Journal of the American Society of Hematology"},{"issue":"9","key":"2025083006312293100_ref19","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Research"},{"issue":"12","key":"2025083006312293100_ref20","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1093\/jpp\/rgac063","article-title":"Doxorubicin-induced cardiotoxicity: Causative factors and possible interventions","volume":"74","author":"Jones","year":"2022","journal-title":"Journal of Pharmacy and Pharmacology"},{"issue":"28","key":"2025083006312293100_ref21","doi-asserted-by":"crossref","first-page":"25883","DOI":"10.18632\/oncotarget.4540","article-title":"ABT-263 induces apoptosis and synergizes with chemotherapy by targeting stemness pathways in esophageal cancer","volume":"6","author":"Chen","year":"2015","journal-title":"Oncotarget"},{"issue":"3","key":"2025083006312293100_ref22","doi-asserted-by":"crossref","first-page":"e5289","DOI":"10.1002\/bmc.5289","article-title":"Validation of a robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of navitoclax","volume":"36","author":"Scott","year":"2022","journal-title":"Biomedical Chromatography"},{"key":"2025083006312293100_ref23","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jchromb.2017.11.020","article-title":"Determination of non-liposomal and liposomal doxorubicin in plasma by LC\u2013MS\/MS coupled with an effective solid phase extraction: In comparison with ultrafiltration technique and application to a pharmacokinetic study","volume":"1072","author":"Xie","year":"2018","journal-title":"Journal of Chromatography B"},{"issue":"1","key":"2025083006312293100_ref24","doi-asserted-by":"crossref","first-page":"18562","DOI":"10.1038\/s41598-020-75662-w","article-title":"Bioanalysis of doxorubicin aglycone metabolites in human plasma samples\u2013implications for doxorubicin drug monitoring","volume":"10","author":"Siebel","year":"2020","journal-title":"Scientific Reports"},{"key":"2025083006312293100_ref25","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jpba.2018.06.031","article-title":"Optimization of LC method for the quantification of doxorubicin in plasma and urine samples in view of pharmacokinetic, biomedical and drug monitoring therapy studies","volume":"158","author":"Maliszewska","year":"2018","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"issue":"3","key":"2025083006312293100_ref26","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/00007691-199906000-00022","article-title":"An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma","volume":"21","author":"Fogli","year":"1999","journal-title":"Therapeutic Drug Monitoring"},{"issue":"1","key":"2025083006312293100_ref27","doi-asserted-by":"crossref","DOI":"10.1093\/chromsci\/bmad090","article-title":"Bioanalytical method development and validation of doxorubicin and lapatinib in rat plasma using UHPLC-HESI-LTQ-MS","volume":"63","author":"Moinuddin","year":"2025","journal-title":"Journal of Chromatographic Science"},{"issue":"1","key":"2025083006312293100_ref28","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/BF02263888","article-title":"Determination of a new calcium antagonist in human plasma by liquid extraction enrichment and HPLC with UV detection","volume":"36","author":"Flaminio","year":"1993","journal-title":"Chromatographia"},{"issue":"5","key":"2025083006312293100_ref29","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s10337-012-2193-9","article-title":"Rapid isocratic HPLC method and sample extraction procedures for measuring carotenoid, retinoid, and tocopherol concentrations in human blood and breast milk for intervention studies","volume":"75","author":"Turner","year":"2012","journal-title":"Chromatographia"},{"issue":"11","key":"2025083006312293100_ref30","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/BF02490525","article-title":"Development and validation of an HPLC method for determination of amphotericin B in plasma and sputum involving solid phase extraction","volume":"46","author":"Campanero","year":"1997","journal-title":"Chromatographia"},{"issue":"5","key":"2025083006312293100_ref31","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/BF02490427","article-title":"Determination of cimetidine in human plasma by use of coupled-flow injection, solid-phase extraction, and capillary zone electrophoresis","volume":"53","author":"Luo","year":"2001","journal-title":"Chromatographia"},{"issue":"1","key":"2025083006312293100_ref32","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/10408347.2020.1788375","article-title":"Regulatory updates and analytical methodologies for nitrosamine impurities detection in Sartans, ranitidine, nizatidine, and metformin along with sample preparation techniques","volume":"52","author":"Shaik","year":"2022","journal-title":"Critical Reviews in Analytical Chemistry"},{"issue":"1","key":"2025083006312293100_ref33","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1007\/BF02493361","article-title":"Validation issues arising from the new FDA guidance for industry on bioanalytical method validation","volume":"55","author":"Brodie","year":"2002","journal-title":"Chromatographia"},{"key":"2025083006312293100_ref34"},{"issue":"2","key":"2025083006312293100_ref35","doi-asserted-by":"publisher","first-page":"S203","DOI":"10.1365\/s10337-004-0286-9","article-title":"The validation of a bioanalytical method for the determination of fluconazole in human plasma","volume":"59","author":"Hillis","year":"2004","journal-title":"Chromatographia"},{"issue":"1","key":"2025083006312293100_ref36","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1007\/BF02493122","article-title":"The validation of bioanalytical methods in unusual or multiple matrices during human drug development","volume":"52","author":"Clark","year":"2000","journal-title":"Chromatographia"},{"issue":"1","key":"2025083006312293100_ref37","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1007\/BF02493363","article-title":"Matrix effects and selectivity issues in LC-MS-MS","volume":"55","author":"Smeraglia","year":"2002","journal-title":"Chromatographia"},{"issue":"6","key":"2025083006312293100_ref38","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jpha.2017.05.004","article-title":"Development and validation of a high throughput LC\u2013MS\/MS method for simultaneous quantitation of pioglitazone and telmisartan in rat plasma and its application to a pharmacokinetic study","volume":"7","author":"Sengupta","year":"2017","journal-title":"Journal of Pharmaceutical Analysis"},{"issue":"6","key":"2025083006312293100_ref39","doi-asserted-by":"crossref","first-page":"e4186","DOI":"10.1002\/bmc.4186","article-title":"Development and validation of LC-MS\/MS method for simultaneous determination of sofosbuvir and daclatasvir in human plasma: Application to pharmacokinetic study","volume":"32","author":"Abdallah","year":"2018","journal-title":"Biomedical Chromatography"},{"issue":"1","key":"2025083006312293100_ref40","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.chroma.2006.08.083","article-title":"Chromatographic quantitation at losses of analyte during sample preparation: Application of the modified method of double internal standard","volume":"1150","author":"Zenkevich","year":"2007","journal-title":"Journal of Chromatography A"},{"issue":"1","key":"2025083006312293100_ref41","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.chroma.2005.02.057","article-title":"Determination of (fluoro)quinolone antibiotic residues in pig kidney using liquid chromatography\u2013tandem mass spectrometry: I","volume":"1088","author":"Toussaint","year":"2005","journal-title":"Laboratory-validated method. Journal of Chromatography A"}],"container-title":["Journal of Chromatographic Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/chromsci\/article-pdf\/63\/8\/bmaf046\/64165718\/bmaf046.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/chromsci\/article-pdf\/63\/8\/bmaf046\/64165718\/bmaf046.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T10:31:33Z","timestamp":1756549893000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/chromsci\/article\/doi\/10.1093\/chromsci\/bmaf046\/8244557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,30]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,30]]}},"URL":"https:\/\/doi.org\/10.1093\/chromsci\/bmaf046","relation":{},"ISSN":["0021-9665","1945-239X"],"issn-type":[{"type":"print","value":"0021-9665"},{"type":"electronic","value":"1945-239X"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,8,30]]},"article-number":"bmaf046"}}